ReviewFrontiers in endocrinology2022
Androgen receptor in breast cancer: The "5W" questions.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Vitamin D Supplementation and Testosterone Levels in Breast Cancer Survivors.International journal of molecular sciences · 2025Trial
- Article
- The Non-Coding rs5945619 Variant at Xp11.22 and Its Putative Regulatory Effects on Nearby Genes in Ecuadorian Mestizo Women with Breast Cancer: A Case Series and In Silico Cis-eQTL Analysis.International journal of molecular sciences · 2026Article
- An Update on the Role of Androgens and Androgen Receptor in Triple-Negative Breast Cancer.Cells · 2026Review
- DNA Methylation in Blood Samples from Malignant Mammary Tumors of Companion Dogs: A Pilot Study.Computational and structural biotechnology journal · 2026Article
- Co-targeting ferroptosis and immune evasion through small molecules in breast cancer.Journal of translational internal medicine · 2025Article
- Role of ERβ in Triple-Negative Breast Cancer Associated with p53 and Androgen Receptor.International journal of molecular sciences · 2025Article
- Androgen Receptor: Clinical Importance in Breast Cancer Patients Receiving CDK 4/6 Inhibitor Treatment.Medicina (Kaunas, Lithuania) · 2025Article
- Androgen Receptors in Human Breast Cancer and Female Canine Mammary Tumors.Molecules (Basel, Switzerland) · 2025Review
- Androgen receptor expression distribution characteristics in young female breast cancer patients in China: a study of clinicopathological features.Translational cancer research · 2025Article
- Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer.Breast (Edinburgh, Scotland) · 2025Review
- Androgen receptor activation promotes tumor progression in canine and human triple negative breast cancer cell lines.Frontiers in veterinary science · 2025Article
- Lathyrol affects the expression of AR and PSA and inhibits the malignant behavior of RCC cells.Open medicine (Warsaw, Poland) · 2025Article
- Predictive and Prognostic Values of Glycoprotein 96, Androgen Receptors, and Extranodal Extension in Sentinel Lymph Node-Positive Breast Cancer: An Immunohistochemical Retrospective Study.Journal of clinical medicine · 2024Article
- Article
- Bicalutamide Enhances Conventional Chemotherapy in In Vitro and In Vivo Assays Using Human and Canine Inflammatory Mammary Cancer Cell Lines.International journal of molecular sciences · 2024Article
- Androgen receptor activity inversely correlates with immune cell infiltration and immunotherapy response across multiple cancer lineages.bioRxiv : the preprint server for biology · 2024Article
- Frequency of Androgen Receptor Positivity in Tumors: A Study Evaluating More Than 18,000 Tumors.Biomedicines · 2024Article
- AIbZIP/CREB3L4 Promotes Cell Proliferation via the SKP2-p27 Axis in Luminal Androgen Receptor Subtype Triple-Negative Breast Cancer.Molecular cancer research : MCR · 2024Article
- Determination of the androgen receptor status of disseminated tumor cells in primary breast cancer patients.Archives of gynecology and obstetrics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Androgen receptor (AR) is expressed in 60-70% of breast cancers (BCs) and the availability of anti-AR compounds, currently used for treating prostate cancer, paves the way to tackle specifically AR-positive BC patients. The prognostic and predictive role of AR in BC is a matter of debate, since the results from clinical trials are not striking, probably due to both technical and biological reasons. In this review, we aimed to highlight WHAT is AR, describing its structure and functions, WHAT to test and HOW to detect AR, WHERE AR should be tested (on primary tumor or metastasis) and WHY studying this fascinating hormone receptor, exploring and debating on its prognostic and predictive role. We considered AR and its ratio with other hormone receptors, analyzing also studies including patients with ductal carcinoma
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.